Yiling Pharmaceutical (002603), a 3 times big bull stock, has become the focus of heated discussions in the market. On April 18, Yiling Pharmaceutical opened the market at the limit-down price of 32.39 yuan per share, which was the second limit-down price for the company’s stock price in a row. Behind the stock price falling by the limit one after another, the matter involved Lianhua Qingwen, a product of Yiling Pharmaceutical. On April 17, Dr. Lilac published the article “Don’t eat Lianhua Qingwen to prevent the new crown” on his official Weibo, and the article was swiped on the Internet for a while.
access:
VIP members buy 1 and get 5: Free iQIYI half-year card, JD Plus, Baidu Netdisk, Dingdong grocery shopping
Going back further, on April 14, Wang Sicong forwarded a video on his Weibo, “WHO “recommended” Lianhua Qingwen, who told you? “. Yiling Pharmaceutical’s share price suffered a severe setback under the successive doubts of Dr. Wang Sicong and Dr. Clove. Regarding the above-mentioned online public opinion, although Yiling Pharmaceutical has not issued an announcement to clarify, it has also issued a thousand-character response on the interactive platform, saying that “clear people will clear themselves”, and will protect their legitimate rights and interests through legal means when necessary.
Shares drop again
Over 130,000 shareholders of Yiling Pharmaceuticals “eat” the limit again.
According to the trading market, on April 18, Yiling Pharmaceutical opened the market at the limit-down price of 32.39 yuan per share. After the opening, there was a huge selling order of 154 million yuan. As of the press release of the Beijing Business Daily, the stock price of Yiling Pharmaceuticals has been locked down, with a total market value of 54.11 billion yuan, and more than 400,000 sell orders are lining up to sell in the first position.
It should be pointed out that this is not the first time for Yiling Pharmaceutical to drop by the limit. On the previous trading day, that is, on April 15, the company’s stock price also closed at the limit. As of the close on April 14, the total market value of Yiling Pharmaceuticals was 66.812 billion yuan. According to calculations, the company’s total market value has shrunk by 12.702 billion yuan in the two trading days.
On the news, on April 17, Dr. Lilac published the article “Don’t eat Lianhua Qingwen to prevent the new crown” on his official Weibo. The article elaborated that under the current scientific conditions, the following three measures can be used to prevent the new crown. , the first, physical blockade, that is, the routinely used new coronavirus prevention methods, including wearing masks, maintaining social distance, etc.; the second induces an immune response and reduces the infectivity of the released virus; the third pre-exposure prophylaxis (PrEP) ), which means that you are not currently infected with the virus and have not been exposed to high-risk environments, and you should take medicine in advance to prevent infection.
After discussing in detail the three measures to prevent the new crown, Dr. Lilac came to the conclusion that among the three methods currently known, even Hua Qingwen was not established and could not achieve the effect of preventing the new crown virus, and said that if you are not sick, do not eat indiscriminately. Medicine, even Hua Qingwen.
Before Dr. Lilac, on April 14, Wang Sicong reposted a video on Weibo, “WHO “recommended” Lianhua Qingwen, who told you? “, and wrote in the retweet, “The China Securities Regulatory Commission should strictly investigate Yiling Pharmaceutical”, but the retweet was later deleted.
Under the successive doubts of Dr. Wang Sicong and Dr. Clove, the stock price of Yiling Pharmaceutical continued to drop by the limit. Wei Zining, a medical reform expert, told a reporter from Beijing Business Daily that there are clinical experimental studies on the efficacy of related medicines, and investors should be cautious about some Internet celebrities and other remarks.
According to Dr. Lilac’s official WeChat account, the main body of the certification is Hangzhou Lianke Meixun Biomedical Technology Co., Ltd., and the actual controller is Li Tiantian.
A reporter from Beijing Business Daily learned that in recent years, Dr. Lilac has been controversial in the market, and the pastoralism incident in August 2021 caused heated discussions in the market. According to media reports, the pastoral whole-wheat bread was named by the Shanghai Consumer Protection Committee, saying that its nutritional ingredients were falsely labeled, and the actual calories far exceeded the labeled value.
In response to related issues, reporters from Beijing Business Daily called Yiling Pharmaceutical’s board secretary office many times for interviews, but they were always “busy on the phone”.
The company fights back: the clearer is self-clearing
Regarding online public opinion, Yiling Pharmaceutical has not yet made a clarification in the announcement, but the company has fought back on the interactive platform.
On the interactive platform of the Shenzhen Stock Exchange, many investors asked Yiling Pharmaceutical about the above-mentioned online public opinion issues, and some of them said, “There have been a lot of news on the Internet recently questioning the efficacy of Lianhua Qingwen’s treatment and prevention of the new crown. I hope the company can Stand up and speak up.”
In response, Yiling Pharmaceutical responded with a long text of more than 1,000 words. Yiling Pharmaceutical said that the company has also paid attention to the relevant public opinion on the Internet, believes that “the clearer will clear itself”, and will continue to track the development of the situation, and will protect its legitimate rights and interests through legal means when necessary.
In addition, Yiling Pharmaceutical emphasized that Lianhua Qingwen was developed during the prevention and control of the SARS epidemic in 2003, played an important role in the prevention and control of influenza A in 2009, and has made significant contributions to the prevention and control of the new crown pneumonia epidemic since 2020. , has registered applications in Hong Kong, Macau and nearly 30 countries. A number of domestic authoritative scientific research institutions have carried out a series of basic and clinical researches on Lianhua Qingwen’s anti-new coronary pneumonia, forming a “cell-animal-preventive drug-clinical treatment” evidence chain for the prevention and treatment of new coronary pneumonia. strain and its mutant strains Delta, Omicron, etc. have obvious inhibitory effect.
In addition, Yiling Pharmaceutical introduced that the company has published 35 experimental and clinical research papers (15 published abroad), among which “Efficacy and Safety Study of Lianhua Qingwen Capsule in the Prevention of Novel Coronavirus Pneumonia: Prospective Open Label” Controlled Trials” real-world research paper published in the international journal Evidence-Based Complementary and Alternative Medicine. The results of the study confirmed that the positive rate of nucleic acid detection in the Lianhua Qingwen intervention group was 0.27%, which was significantly lower than the positive rate of 1.14% in the control group (with statistical significance), and the preventive application of Lianhua Qingwen in the close contact group could reduce the positive infection rate of new coronary pneumonia by 76%. , while the security is good.
According to the data, Yiling Pharmaceutical was listed in July 2011. The company’s main business is the research and development, production and sales of patented innovative traditional Chinese medicines. Since the outbreak of the epidemic, the company’s stock price and performance have both risen sharply with Lianhua Qingwen products. The company’s stock price has more than tripled since 2020 (statistics in the form of resumption of rights in the future), and the company’s net profit has doubled in 2020.
As of now, Yiling Pharmaceutical has not disclosed its 2021 full-year results, but the company’s attributable net profit in the first three quarters of 2021 is about 1.224 billion yuan, a year-on-year increase of 20.43%. Economist Song Qinghui told a reporter from Beijing Business Daily that investors should take the fundamentals of the company as the fundamental when investing in the secondary market.
From the perspective of product revenue composition, the 2020 annual report shows that the main products of Yiling Pharmaceutical include cardiovascular and cerebrovascular products, respiratory system products, other patented products, and other products. Among them, the operating income of respiratory system products is about 4.256 billion yuan, accounting for about 4.256 billion yuan. Up to 48.46%, and in 2019, the revenue of this product accounted for 29.24%.